Arrhythmias & electrophysiology
High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial
Authors' conclusion
In this first-in-human study, the high-voltage PFA catheter efficiently delivered transmural ventricular lesions to treat scar-related VT.
Study context
- Population
- Patients with scar-related ventricular tachycardia (VT) (ischemic or nonischemic substrate)
- Participants
- 26 patients
- Outcome
- Acute procedural success
Methodological details2 centres
- 2 centres
Main finding
As reported in the abstract
Acute procedural success, patients
24
92%
Lesions per patient, median (IQR)
21
14–24
Ablation time, minutes (IQR)
31
19–42
Further findings
Clinical VT inducibility, before vs after ablation
- Clinical VT induced before ablation
- 14 of 16 patients (88%)
- Clinical VT induced after ablation
- 1 of 16 patients (6%, P<0.001)
Transmural tissue homogenization after endocardial-only pulsed field ablation (PFA)
- Epi-endo voltage mapping performed
- 10 patients [42%]
- Transmural homogenization in endocardial-only PFA
- 9 (100%)
VT/VF burden, baseline vs after PFA
- Incidence rate of VT/VF decreased by
- 98%
- Baseline, median [IQR]
- 6 [1-11]
- After PFA, median [IQR]
- 0 [0-0]
- P
- P < 0.001
Safety
Primary safety end points (cardiogenic shock, HF hospitalisation, retroperitoneal bleed) · within 180 days
- Patients with a primary safety end point
- 3 of 26 (11.5%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →